



CLINICAL INSIGHTS

EXCEL Division of Blue Cross Laboratories

ETERBA-MAD TAB/ ETERNA SYRUP/ ETERNA INJ

Issue I, No.2, 2026

Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis

Freedman BS et.al; N Engl J Med; 2025 Jul 17;393(3):255-266.

- A double-blind, randomized superiority trial was conducted to check the outcomes of Ondansetron in children having gastroenteritis-associated vomiting.
- A total of 1030 children from 6 months to less than 18 years of age underwent randomization.
- In response to persistent vomiting within the first 48 hours following enrollment, six doses of oral ondansetron or placebo were given; 5.1% of the ondansetron group and 12.5% of the placebo group experienced moderate-to-severe gastroenteritis.
- Ondansetron had fewer vomiting episodes overall within 48 hours after enrollment than placebo. Additionally, there was no significant difference in the incidence of adverse events between the groups.

Compared to a placebo, Ondansetron decreased the incidence of moderate-to-severe gastroenteritis in children who had gastroenteritis-related vomiting over the seven days that followed an ER visit.

